Welcome to our dedicated page for Aeon Biopharma SEC filings (Ticker: AEON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to decode AEON Biopharma’s merger accounting notes or ABP-450 trial updates buried inside its latest 10-K? Our platform turns hundreds of biotech-specific pages into clear insights in minutes. Stock Titan’s AI-powered summaries spotlight cash runway disclosures, FDA milestone risks, and AEON Biopharma annual report 10-K simplified so you can focus on what moves the share price.
Every regulatory document—whether a fast-moving AEON Biopharma 8-K material events explained, a detailed AEON Biopharma quarterly earnings report 10-Q filing, or AEON Biopharma insider trading Form 4 transactions—appears here the moment it hits EDGAR. Our AI tags sections discussing ABP-450 efficacy data, merger-related goodwill, or PIPE financing, then delivers plain-English takeaways. Need the raw numbers? Download full text and exhibits or skim our red-line comparisons between quarters.
Common investor tasks become simple:
- Track AEON Biopharma Form 4 insider transactions real-time and spot patterns before trial readouts.
- Compare R&D spend across periods with one click using our AEON Biopharma earnings report filing analysis.
- Review AEON Biopharma proxy statement executive compensation without scrolling through boilerplate.
Whether you are understanding AEON Biopharma SEC documents with AI for the first time or monitoring daily updates, our coverage of 10-K, 10-Q, Form 4, S-4, and more delivers the detail serious biotech investors need—minus the complexity.
On 07 July 2025, Sapient Capital LLC submitted Amendment No. 1 to Schedule 13G disclosing its current position in Intensity Therapeutics, Inc. (ticker: INTS). As of the event date 06 June 2025, the registered investment adviser reports beneficial ownership of 976,797 common shares, equal to 3.9 % of the outstanding stock. All shares are held with shared dispositive power and zero voting power, underscoring a passive investment stance with no intent to influence control of the company. Because the holding has fallen below the 5 % threshold, this amendment serves primarily to update Sapient’s prior 13G filing and confirm continued compliance with Section 13(d) reporting rules.
The filing classifies Sapient Capital as an “investment adviser” under Rule 13d-1(b)(1)(ii)(E) and includes the standard certification that the shares were acquired in the ordinary course of business. No sale, purchase price, or transaction timetable is provided, and there are no indications of governance initiatives or strategic agreements between the investor and the issuer. For shareholders, the disclosure is informational rather than directive: while a near-million-share position is material enough to track, Sapient’s <4 % stake and lack of voting authority limit its potential influence on Intensity Therapeutics’ operations or board decisions.
FAQ
What is the current stock price of Aeon Biopharma (AEON)?
What is the market cap of Aeon Biopharma (AEON)?
What is the primary focus of AEON Biopharma?
How did the recent merger impact AEON Biopharma?
What distinguishes AEON Biopharma in the biopharmaceutical industry?
Can you explain the company’s clinical-stage pipeline?
What role does the sponsor team play in AEON Biopharma?
How does AEON Biopharma ensure quality and transparency in its operations?
What is the significance of the company’s focus on the neurosciences market?
How does AEON Biopharma manage clinical and operational risks?
